Glycyrrhetinic acid structure
|
Common Name | Glycyrrhetinic acid | ||
---|---|---|---|---|
CAS Number | 471-53-4 | Molecular Weight | 470.684 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 588.3±50.0 °C at 760 mmHg | |
Molecular Formula | C30H46O4 | Melting Point | 292 - 295ºC | |
MSDS | N/A | Flash Point | 323.7±26.6 °C | |
Symbol |
GHS07 |
Signal Word | Warning |
Use of Glycyrrhetinic acid18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. |
Name | Enoxolone |
---|---|
Synonym | More Synonyms |
Description | 18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. |
---|---|
Related Catalog | |
Target |
Human Endogenous Metabolite |
In Vitro | 18β-Glycyrrhetinic acid is the major bioactive component of Glycyrrhizae Radix and possesses anti-ulcerative, anti-inflammatory and antiproliferative properties. MTS assay demonstrates that 24 h treatment of 18β-Glycyrrhetinic acid suppresses cell proliferation in both cell lines in a dose-dependent manner. 18β-Glycyrrhetinic acid at 160 μM significantly decreases the percentage of viable cells to around 40.5±10.5% in A549 and 38.3±4.6% in NCI-H460 (p<0.01 respectively). When the cells are treated with 320 μM 18β-Glycyrrhetinic acid, a greater inhibitory effects on cell proliferation is shown, as the percentage of viable cells is below 30% compare with untreated controls (p<0.001). Treatment with 18β-Glycyrrhetinic acid at 160 μM and 320 μM decreases the levels of full-length PARP and increases the levels of cleaved-PARP[1]. |
In Vivo | Rats in 18β-Glycyrrhetinic acid+Triptolide (TP) group which receive low-dose 18β-Glycyrrhetinic acid (50 mg/kg) have significant reductions in the three serum parameters when compare with TP rats. Rats in 18β-Glycyrrhetinic acid+TP group which receive the high-dose 18β-Glycyrrhetinic acid (100 mg/kg) have slightly lowered the levels of three liver enzymes, the reductions do not reach statistical significance compare with TP group. Contrastingly, preadministration of low-dose 18β-Glycyrrhetinic acid protects animals from TP-induced hepatic lesions. On the contrary, low-dose 18β-Glycyrrhetinic acid (50 mg/kg) markedly suppresses the release of the four cytokines above[3]. |
Cell Assay | Primary microglia cultures are used in this study. For treatment assay, microglia are incubated with complete DMEM and stimulated with or without 100 ng/mL IFN-γ in the presence or absence of 18β-Glycyrrhetinic acid (25 μM and 50 μM) at 37°C in a humidified incubator with 5% CO2. For cell migration assay, the isolated primary microglia that seeded in complete DMEM medium are stimulated with or without IFN-γ (100 ng/mL), and treated with different doses of 18β-Glycyrrhetinic acid, 24 h later, the microglia culture supernatants are collected and added to the lower chambers of Transwell inserts[2]. |
Animal Admin | Healthy Wistar rats (male, 200±20 g) are used and divided into five groups with 10 individuals for each group randomly. Animals in normal control (NC) group receive distilled water for 6 days and 0.5% CMC-Na for the last 3 days. Rats in Triptolide model group (TP), 18β-Glycyrrhetinic acid low-dose group (GAL+TP), and 18β-Glycyrrhetinic acid high-dose group (GAH+TP) receive distilled water, 18β-Glycyrrhetinic acid (50 mg/kg, p.o., dissolved in distilled water), or 18β-Glycyrrhetinic acid (100 mg/kg, p.o., dissolved in distilled water) for consecutive 6 days, respectively, and liver injury is induced by TP (2.4 mg/kg, p.o., suspended in 0.5% CMC-Na) for the last 3 days. Animals in the above three groups receive TP 6 hours after distilled water or 18β-Glycyrrhetinic acid treatment on the last 3 days[3]. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 588.3±50.0 °C at 760 mmHg |
Melting Point | 292 - 295ºC |
Molecular Formula | C30H46O4 |
Molecular Weight | 470.684 |
Flash Point | 323.7±26.6 °C |
Exact Mass | 470.339600 |
PSA | 74.60000 |
LogP | 6.57 |
Vapour Pressure | 0.0±3.7 mmHg at 25°C |
Index of Refraction | 1.563 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
Symbol |
GHS07 |
---|---|
Signal Word | Warning |
Hazard Statements | H302-H319 |
Precautionary Statements | P301 + P312 + P330-P305 + P351 + P338 |
Hazard Codes | Xn: Harmful; |
Risk Phrases | R22;R36 |
Safety Phrases | 22-24/25 |
RIDADR | NONH for all modes of transport |
WGK Germany | 3 |
RTECS | RK0180000 |
HS Code | 2938909030 |
Precursor 8 | |
---|---|
DownStream 6 | |
HS Code | 2918990090 |
---|---|
Summary | 2918990090. other carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulphonated, nitrated or nitrosated derivatives. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin.
Int. J. Pharm. 478(2) , 553-68, (2015) Hepatocellular carcinoma (HCC) dual targeted stimuli responsive nanoparticles (NPs) for intracellular delivery of doxorubicin (DOX) were developed based on a reduction cleavable hyaluronic acid-glycyr... |
|
Two-step inhibitory effect of kanzo on oxytocin-induced and prostaglandin F2α-induced uterine myometrial contractions.
J. Nat. Med. 68(3) , 550-60, (2014) We previously reported that shakuyaku-kanzo-to, a kampo medicine consisting of shakuyaku and kanzo, has an inhibitory effect on myometrial contractions in pregnant women. In this study, we evaluated t... |
|
Prevention of cisplatin-induced ototoxicity by the inhibition of gap junctional intercellular communication in auditory cells. Kim YJ, Kim J, Tian C, et al.
Cell. Mol. Life Sci. 71(19) , 3859-71, (2014)
|
MFCD00003706 |
(3β)-3-Hydroxy-11-oxoolean-12-en-30-oic acid |
Glycyrrhetinic acid |
(2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-Hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydro-2-picenecarboxylic acid |
18-beta-Glycyrrhetinic acid |
Arthrodont |
EINECS 207-444-6 |
18-β-Glycyrrhetinic Acid |
glycyrrhetin |
GM 1658 |
Uralenic acid |
3β-Hydroxy-11-oxoolean-12-en-30-oic acid |
18b-Glycyrrhetic acid |
Biosone |
Olean-12-en-30-oic acid, 3β-hydroxy-11-oxo- |
18β-Glycyrrhetinic acid |
STX 352 |
Glycyrrhetic Acid |
PO 12 |
Olean-12-en-30-oic acid, 3-hydroxy-11-oxo-, (3β)- |
3b-Hydroxy-11-oxoolean-12-en-30-oic Acid |
18b-Glycyrrhetinic Acid |
Glycyrrhetinate |
(3b,20b)-3-Hydroxy-11-oxoolean-12-en-29-oic Acid |
ENOLOXONE |
enoxolone |